Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Nanno H, Mulder"'
Publikováno v:
Drug Target Insights, Vol 2, Pp 105-109 (2007)
Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to re
Externí odkaz:
https://doaj.org/article/0db588fd9f004c16a9e02fd6f6503d70
Publikováno v:
Drug Target Insights, Vol 2, Iss 1 (2007)
Abstract non disponibile
Externí odkaz:
https://doaj.org/article/ac8d661f913e42758a88709d15490cce
Autor:
René C. J. Verschueren, Pax H. B. Willemse, Jan Buter, Dirk Th. Sleijfer, Elisabeth G. E. de Vries, Harm A. M. Sinnige, Nanno H. Mulder, Winette T. A. van der Graaf
Publikováno v:
Cancer. 75:1072-1076
Background. A Phase II study of combination treatment with 5-fluorouracil (5-FU), leucovorin (LV), and interferon alpha-2a (IFN) in patients with previously untreated metastatic colorectal cancer was previously reported by the authors. Therapy was on
Autor:
Wouter B, Nagengast, Marjolijn N Lub-de, Hooge, Esther M E, van Straten, Schelto, Kruijff, Adrienne H, Brouwers, Wilfred F A, den Dunnen, Johan R, de Jong, Harry, Hollema, Rudi A, Dierckx, Nanno H, Mulder, Elisabeth G E, de Vries, Harald J, Hoekstra, Geke A P, Hospers
Publikováno v:
European journal of cancer (Oxford, England : 1990). 47(10)
A feasibility study was performed to investigate the presence of VEGF in melanoma lesions by VEGF-SPECT with (111)In-bevacizumab. In addition the effect of a single therapeutic bevacizumab dose on (111)In-bevacizumab uptake was compared with VEGF lev
Publikováno v:
Anticancer research. 27(4B)
Cornea-derived transcript 6 (CDT6, also known as AngX) is an angiopoietin-related factor resulting in anti-tumour effect in vivo. However, a recent abstract reported that CDT6 can also induce angiogenesis and promotes tumour growth. In our previous w
Autor:
Yoka H, Kusumanto, Nanno H, Mulder, Wendy A, Dam, Mario, Losen, Mario H, Losen, Marc H, De Baets, Coby, Meijer, Geke A P, Hospers
Publikováno v:
Drug Delivery, 14(5), 273-277. Taylor & Francis Group
Plasmid-based gene delivery to muscle is a treatment strategy for many diseases with potential advantages above viral-based gene delivery methods, however, with a relative low transfection efficiency. We compared two physical methods-electroporation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71c9da535cb2dcea2edbc18f78bf1c7a
https://research.rug.nl/en/publications/0629d321-9c8a-4234-adf1-115be2ce8773
https://research.rug.nl/en/publications/0629d321-9c8a-4234-adf1-115be2ce8773
Autor:
Bareld B, Pultrum, Henderik L, van Westreenen, Nanno H, Mulder, Hendrik M, van Dullemen, John Th M, Plukker
Publikováno v:
Anticancer research. 26(3B)
The outcome of different palliative regimens was investigated in patients with incurable oesophageal carcinoma identified during surgical exploration.Between January 1992 and December 2002, 203 patients with oesophageal cancer underwent surgery after
Autor:
Anne Rixt Buursma, Vera Rutgers, Geke A.P. Hospers, Nanno H. Mulder, Willem Vaalburg, Erik F.J. de Vries
Publikováno v:
Nuclear medicine communications. 27(1)
Objective The herpes simplex virus thymidine kinase (HSVtk) gene has frequently been applied as a reporter gene for monitoring transgene expression in animal models. In clinical gene therapy protocols, however, extremely low expression levels of the
Autor:
Ingrid J, Van Dillen, Nanno H, Mulder, Wim J, Sluiter, Coby, Meijer, Steven, De Jong, Jadranka, Loncarek, Marc, Mesnil, Erik F J, De Vries, Willem, Vaalburg, Geke A P, Hospers
Publikováno v:
Anticancer research. 25(1A)
This paper focuses on the influence of chemoresistance on the herpes simplex virus (HSV-tk)/ganciclovir (GCV)-induced bystander effect (BE), as studied in a human small cell lung cancer (SCLC) cell line (GLC4) and its sublines with in vitro acquired
Autor:
Onne, Reerink, Nanno H, Mulder, René C J, Verschueren, Theo, Wiggers, Ben G, Szabo, Geke A P, Hospers
Publikováno v:
Anticancer research. 25(1B)
The aim was to determine the maximum tolerable dose of oxaliplatin added to (oral) 5FU in irresectable rectal cancer.Nineteen patients were treated; 13 patients received 5FU/LV and 6 patients capecitabine. Oxaliplatin was administered on days 1 and 2